Cyclacel Pharmaceuticals’ CEO Discusses Q4 2013 Results – Earnings Call Transcript

[at Seeking Alpha] – Spiro Rombotis Thank you, Bill and good afternoon. During 2013, we continued to progress clinical development of sapacitabine in patients with acute myeloid leukemia or AML and myelodysplastic syndromes … more

View todays social media effects on CYCC

View the latest stocks trending across Twitter. Click to view dashboard

See who Cyclacel is hiring next, click here to view